ATXS Quote, Financials, Valuation and Earnings

Hologic, Inc. has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of 17.85%. Astria Therapeutics, Inc.'s return on equity of -42.95% beat Hologic, Inc.'s return on equity of 11.59%.

Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 95.55%. On the other hand Hologic, Inc. has an analysts' consensus of $76.92 which suggests that it could grow by 2.41%. Given that Astria Therapeutics, Inc. has higher upside potential than Hologic, Inc., analysts believe Astria Therapeutics, Inc. is more attractive than Hologic, Inc..

Astria Therapeutics, Inc. has a beta of 0.016, which suggesting that the stock is 98.408% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.493%.

Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend.

Astria Therapeutics, Inc. quarterly revenues are $706K, which are smaller than Hologic, Inc. quarterly revenues of $1B. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than Hologic, Inc.'s net income of $187.3M. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while Hologic, Inc.'s PE ratio is 30.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,026.58x versus 4.16x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of -255.85%. Astria Therapeutics, Inc.'s return on equity of -42.95% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 95.55%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.49%. Given that Astria Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Astria Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Astria Therapeutics, Inc. has a beta of 0.016, which suggesting that the stock is 98.408% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Astria Therapeutics, Inc. quarterly revenues are $706K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,026.58x versus 10.65x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical, Inc. has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of -11.09%. Astria Therapeutics, Inc.'s return on equity of -42.95% beat Orthofix Medical, Inc.'s return on equity of -24.94%.

Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 95.55%. On the other hand Orthofix Medical, Inc. has an analysts' consensus of $22.80 which suggests that it could grow by 64.86%. Given that Astria Therapeutics, Inc. has higher upside potential than Orthofix Medical, Inc., analysts believe Astria Therapeutics, Inc. is more attractive than Orthofix Medical, Inc..

Astria Therapeutics, Inc. has a beta of 0.016, which suggesting that the stock is 98.408% less volatile than S&P 500. In comparison Orthofix Medical, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.22%.

Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. Orthofix Medical, Inc. pays out -- of its earnings as a dividend.

Astria Therapeutics, Inc. quarterly revenues are $706K, which are smaller than Orthofix Medical, Inc. quarterly revenues of $205.6M. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than Orthofix Medical, Inc.'s net income of -$22.8M. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while Orthofix Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,026.58x versus 0.66x for Orthofix Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of --. Astria Therapeutics, Inc.'s return on equity of -42.95% beat Rezolute, Inc.'s return on equity of -63.8%.

Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 95.55%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 29.97%. Given that Astria Therapeutics, Inc. has higher upside potential than Rezolute, Inc., analysts believe Astria Therapeutics, Inc. is more attractive than Rezolute, Inc..

Astria Therapeutics, Inc. has a beta of 0.016, which suggesting that the stock is 98.408% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 61.035%.

Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.

Astria Therapeutics, Inc. quarterly revenues are $706K, which are larger than Rezolute, Inc. quarterly revenues of --. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than Rezolute, Inc.'s net income of -$18.2M. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,026.58x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.